Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400197 | 0.86 | ACHE (0.60) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL30163718 | 0.80 | ACHE (0.60) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9513038 | 0.80 | ACHE (0.60) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7569673 | 0.80 | ACHE (0.81) | ACHEEPHX2 | |
| SCHEMBL10939707 | 0.80 | ACHE (0.81) | ACHEEPHX2 | |
| SCHEMBL3975468 | 0.80 | ACHE (0.88) | ACHEEPHX2 | |
| SCHEMBL14996209 | 0.80 | ACHE (0.64) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21001852 | 0.79 | MEN1 (0.60) | ACHE | |
| SCHEMBL13387437 | 0.78 | ACHE (0.85) | ACHEEPHX2 | |
| SCHEMBL2853012 | 0.78 | ACHE (0.85) | ACHEEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435409-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136493-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |